Lilly, Incyte Treatment Continues to Impress

Lilly completed the CoLucid acquisition in March.

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced positive results in two phase 3 studies. The company says rheumatoid arthritis treatment baricitinib effectively treated pain, stiffness and fatigue and helped induce clinical remission.

The results mark the third and fourth successful phase 3 studies of baricitinib, which is being developed by Lilly and Incyte Corp. (Nasdaq: INCY). The companies announced a worldwide license and collaboration agreement to develop and commercialize baricitinib. In addition to the phase 3 trials for rheumatoid arthritis treatment, baricitinib is in phase 2 development for psoriasis, diabetic nephropathy and atopic dermatitis.

Last week, Lilly detailed plans for a $70 million interdisciplinary laboratory in Indianapolis. The company says the lab will be a key piece of its "Next Generation Development" initiative, which aims to develop new medicines in half the time.